PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

Phase 1 Unknown 18 enrolled University Hospital, Geneva

NaSequentialOpen-labelTreatment

Summary

Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.

Timeline

Start: 2020-11-11
Primary completion: 2023-12-12
Completion: 2024-12

Publications

Lang N, Diciola A, Labidi-Galy I, Ris F, Di Marco M, Mach N, Petignat P, Toso C, Undurraga M, Hubner M. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open. 2023 Jan 5;13(1):e067691. doi: 10.1136/bmjopen-2022-067691.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	10.5 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	7.5 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	15 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	25 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	37.5 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	52.5 mg/m2	Intrathecal
Subject	Nab-paclitaxel	Small molecule	70 mg/m2	Intrathecal

PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

Summary

Timeline

Publications

Drugs

Indications